Angela OsborneFounder

United Kingdom - ND

Originally a biochemical engineer from UCL, Angela is the CEO and founder of eXmoor pharma, a “trusted one-stop cell and gene therapy partner, accelerating the manufacturing journey from research to patients”, which she founded in 2004. In 2017 eXmoor added process development laboratories to its consultancy base with world leading expertise in viral vector and cell therapy process development. In 2020 eXmoor embarked on a further expansion into GMP manufacturing with its facilities coming on line in 2023. eXmoor currently has 65 employees growing to approx. 200 by 2027.

Prior to starting eXmoor, Angela was Senior Vice President of Pharmaceuticals at Aker Kvaerner, an engineering multinational, where she was responsible for the pharmaceutical business in Europe, growing the turnover to equal the previously dominant chemicals business. Angela started her career at British Biotech, where she built on her PhD, with practical experience of biopharmaceutical process development, scale-up, facility design, validation, and operation of facilities to US and EU GMPs.

Angela is a keen supporter of the BIA, co-founder of the amc (ATMP Manufacturing Community) and active contributor to the UCL MSC in CGT Manufacturing. She enjoys teamwork, problem solving, new challenges and is passionate about developing the CGT industry and creating a CGT cluster in Bristol for the benefit of patients.






Prior to starting eXmoor, I was Senior Vice President of Pharmaceuticals at Aker Kvaerner, an engineering multinational, responsible for the pharmaceutical business in Europe. This grew to approx 500 people working on pharmaceutical engineering projects under my leadership, greatly increasing both turnover and profitability by focussing on key client relationships and developing excellent technical consultants. I started my career at British Biotech, with my first practical experience of biopharmaceutical process design and scale-up, facility design and validation, and operation of facilities to US and European GMPs.

I enjoy teamwork, problem solving and new challenges and am passionate about developing the biopharma and cell therapy industries for the benefit of patients and the economy.